483
Chongqing Kangle Pharmaceutical Co., LtdFDA 483 - Chongqing Kangle Pharmaceutical Co., Ltd - July 23, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Chongqing Kangle Pharmaceutical Co., Ltd in Chongqing, China, a drug manufacturer, revealed a significant issue regarding environmental controls. The firm failed to provide adequate temperature and humidity control in the Solid Raw Material Sampling Room, which is critical for maintaining drug substance product quality. This indicates a potential risk to product integrity due to uncontrolled environmental conditions during raw material sampling.
Open in Dashboard
ID · d8415090-ab91-4e96-82df-e1fd011c3335